| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate |
2008-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f81874d3e0f57845d67496c4c49401fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba372dde97c089bfc3e6a6df048882fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aab6abb0dc3df8322461874fd9a8dd2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cee41e4e3a7fb3b0c82eb35e57fe987
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da98899ca3a169661ea89a74d16e7798 |
| publicationDate |
2010-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20100059912-A |
| titleOfInvention |
Pharmaceutical combination of aliskiren and valsartan |
| abstract |
The present invention a) a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof; And b) a therapeutically effective amount of valsartan or a pharmaceutically acceptable salt thereof A fixed dose oral pharmaceutical combination comprising: wherein the fixed dose oral pharmaceutical combination exhibits in vitro dissolution of up to 60% after 10 minutes and up to 95% after 20 minutes at pH 4.5, At least 25% after 30 minutes and at least 45% after 60 minutes the dissolution profile of component (b) is fixed and the fixed dose oral pharmaceutical combination is biologically equivalent to the free dose combination of aliskiren and valsartan. |
| priorityDate |
2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |